Last reviewed · How we verify

R3-Total targeted treatment with azithromycin

Lihir Medical Centre · FDA-approved active Small molecule Quality 2/100

R3-Total targeted treatment with azithromycin is a Small molecule drug developed by Lihir Medical Centre. It is currently FDA-approved. Also known as: R3-TTT.

At a glance

Generic nameR3-Total targeted treatment with azithromycin
Also known asR3-TTT
SponsorLihir Medical Centre
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about R3-Total targeted treatment with azithromycin

What is R3-Total targeted treatment with azithromycin?

R3-Total targeted treatment with azithromycin is a Small molecule drug developed by Lihir Medical Centre.

Who makes R3-Total targeted treatment with azithromycin?

R3-Total targeted treatment with azithromycin is developed and marketed by Lihir Medical Centre (see full Lihir Medical Centre pipeline at /company/lihir-medical-centre).

Is R3-Total targeted treatment with azithromycin also known as anything else?

R3-Total targeted treatment with azithromycin is also known as R3-TTT.

What development phase is R3-Total targeted treatment with azithromycin in?

R3-Total targeted treatment with azithromycin is FDA-approved (marketed).

Related